The longitudinal of hemoglobin, fatigue and quality of life in anemic cancer patients: Results from five randomised clinical trials

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 979-986

  Cella, D ^a   Kallich, J ^b   McDermott, A ^c   Xu, X ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b AMGEN INC   (United States)

^c Health Economics and Outcomes Research   (United States)

Author keywords

Anemia; Fatigue; Neoplasms; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; EMOTIONAL STABILITY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; GYNECOLOGIC CANCER; HEALTH STATUS; HEMATOLOGIC MALIGNANCY; HUMAN; LINEAR REGRESSION ANALYSIS; LONGITUDINAL STUDY; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; UROGENITAL TRACT CANCER; WELLBEING; ADOLESCENT; BLOOD; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; NEOPLASM; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FATIGUE; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS;

EID: 4644319149     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh235     Document Type: Article

References (27)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634.
2. Mercadante S, Gebbia V, Marrazzo A et al. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303-311.
3. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-19.
4. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-3425.
5. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15: 1218-1234.
6. Yellen SB, Cella DF, Webster KA et al. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy Measurement System. J Pain Symptom Manage 1997; 13: 63-74.
7. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998; 25 (3 Suppl 7): 43-46.
8. Curt G, Breitbart W, Cella D et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5: 353-360.
9. Stone P, Richards M, A'Hern R et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 2000; 11: 561-567.
10. Crawford J, Cella D, Cleeland C et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-895.
11. Gabrilove J, Cleeland C, Livingston R et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
12. Glaspy J, Jadeja J, Justice G et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268-276.
13. Johansson JE, Wersall P, Brandberg Y et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. Scand J Urol Nephrol 2001; 35: 288-294.
14. Kallich J, Tchekmedyian NS, Damiano A et al. Psychological outcomes associated with anemia-related fatigue in cancer patients. Oncology 2002; 16 (9 Suppl): 117-124.
15. Littlewood T, Bajetta E, Nortier JWR et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-2874.
16. Osterborg A, Brandberg Y, Molostova V et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486-2494.
17. Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Onc 2003; 14: 511-519.
18. Glaspy J, Jadeja J, Justice G et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003; 97: 1312-1320.
19. Vansteenkiste J, Pirker R, Massuri B et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211-1220.
20. Smith RE, Tchekmedyian NS, Chan D et al. A dose- and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88: 1851-1858.
21. Hedenus M, Adriansson M, San Miguel J et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394-403.
22. Downie WW, Leatham PA, Rhind VM et al. Studies with pain rating scales. Ann Rheum Dis 1978; 37: 378-381.
23. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures - statistics and strategies for evaluation. Control Clin Trials 1991; 12: 142S-158S.
24. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Hillsdale: Lawrence Erlbaum Associates 1988.
25. Cella D, Eton D, Lai J et al. Combining anchor and distribution based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue Scales. J Pain Symptom Manage 2002; 24: 547-561.
26. Cella D, Lai JS, Chang CH et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-538.
27. Berndt E, Kallich J, Xu X et al. Reductions in anemia and fatigue are associated with improvements in productivity. Blood 2002; 100: 876a (Abstr).